161 related articles for article (PubMed ID: 19934088)
21. ONTARGET: questions asked, questions answered.
Weber MA
J Clin Hypertens (Greenwich); 2008 Jun; 10(6):427-30. PubMed ID: 18550931
[No Abstract] [Full Text] [Related]
22. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
23. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.
Anderson C; Teo K; Gao P; Arima H; Dans A; Unger T; Commerford P; Dyal L; Schumacher H; Pogue J; Paolasso E; Holwerda N; Chazova I; Binbrek A; Young J; Yusuf S;
Lancet Neurol; 2011 Jan; 10(1):43-53. PubMed ID: 20980201
[TBL] [Abstract][Full Text] [Related]
24. ACE inhibitors in cardiovascular disease--unbeatable?
McMurray JJ
N Engl J Med; 2008 Apr; 358(15):1615-6. PubMed ID: 18378521
[No Abstract] [Full Text] [Related]
25. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
[No Abstract] [Full Text] [Related]
26. [Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].
Burnier M; Waeber B; Hess O; Lüscher T
Praxis (Bern 1994); 2008 May; 97(10):559-62. PubMed ID: 18595371
[No Abstract] [Full Text] [Related]
27. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
28. Telmisartan, ramipril, or both in patients at high risk of vascular events.
Büchner N; Banas B; Krämer BK
N Engl J Med; 2008 Jul; 359(4):426. PubMed ID: 18650521
[No Abstract] [Full Text] [Related]
29. Telmisartan, ramipril, or both in patients at high risk of vascular events.
Messerli FH; Bangalore S; Ram VS
N Engl J Med; 2008 Jul; 359(4):426-7; author reply 427. PubMed ID: 18655247
[No Abstract] [Full Text] [Related]
30. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
[TBL] [Abstract][Full Text] [Related]
31. [What is better here: ACE inhibitor or AT1 blocker?].
MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
[No Abstract] [Full Text] [Related]
32. ONTARGET: How much RAS inhibition is enough?
Weder AB
Curr Hypertens Rep; 2009 Feb; 11(1):7-9. PubMed ID: 19146793
[No Abstract] [Full Text] [Related]
33. Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.
Mancia G; Unger T; Zanchetti A
J Hypertens Suppl; 2009 Jul; 27(5):S1. PubMed ID: 19587549
[No Abstract] [Full Text] [Related]
34. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
Cohn JN
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
[TBL] [Abstract][Full Text] [Related]
35. Use of angiotensin receptor blockers after angioedema with an angiotensin-converting enzyme inhibitor.
Haymore BR; DeZee KJ
Ann Allergy Asthma Immunol; 2009 Jul; 103(1):83-4. PubMed ID: 19663135
[No Abstract] [Full Text] [Related]
36. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].
MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381
[No Abstract] [Full Text] [Related]
37. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.
Sleight P
J Hypertens Suppl; 2009 Jul; 27(5):S23-9. PubMed ID: 19587551
[TBL] [Abstract][Full Text] [Related]
38. Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
Liebson PR; Amsterdam EA
Prev Cardiol; 2009; 12(1):43-50. PubMed ID: 19301691
[TBL] [Abstract][Full Text] [Related]
39. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
40. New clinical concepts after the ONTARGET trial.
Ruilope LM; Segura J; Zamorano JL
Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]